These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 33445986)

  • 41. Advances in Protein Degradation.
    Castaldi MP; Fisher SL
    SLAS Discov; 2021 Apr; 26(4):471-473. PubMed ID: 33780295
    [No Abstract]   [Full Text] [Related]  

  • 42. Assays and technologies for developing proteolysis targeting chimera degraders.
    Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
    Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
    Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CETSA and thermal proteome profiling strategies for target identification and drug discovery of natural products.
    Tu Y; Tan L; Tao H; Li Y; Liu H
    Phytomedicine; 2023 Jul; 116():154862. PubMed ID: 37216761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lessons from natural molecular glue degraders.
    Cao S
    Biochem Soc Trans; 2024 Jun; 52(3):1191-1197. PubMed ID: 38864421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation.
    Gross PH; Sheets KJ; Warren NA; Ghosh S; Varghese RE; Wass KWass KE; Kadimisetty K
    Biochem Biophys Res Commun; 2022 Nov; 628():68-75. PubMed ID: 36084553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure driven compound optimization in targeted protein degradation.
    Leissing TM; Luh LM; Cromm PM
    Drug Discov Today Technol; 2020 Dec; 37():73-82. PubMed ID: 34895657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
    Rothweiler EM; Brennan PE; Huber KVM
    Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications.
    Stacey P; Lithgow H; Lewell X; Konopacka A; Besley S; Green G; Whatling R; Law R; Röth S; Sapkota GP; Smith IED; Burley GA; Harling J; Benowitz AB; Queisser MA; Muelbaier M
    SLAS Discov; 2021 Aug; 26(7):885-895. PubMed ID: 34041938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developments of PROTACs technology in immune-related diseases.
    Wang C; Zhang Y; Deng J; Liang B; Xing D
    Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution.
    Xiao Y; Yuan Y; Liu Y; Lin Z; Zheng G; Zhou D; Lv D
    J Med Chem; 2024 Jul; 67(14):11580-11596. PubMed ID: 38981094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
    Moon S; Lee BH
    Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications.
    Li Q; Zhou L; Qin S; Huang Z; Li B; Liu R; Yang M; Nice EC; Zhu H; Huang C
    Eur J Med Chem; 2023 Sep; 257():115447. PubMed ID: 37229829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
    Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
    Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.